Health technology assessment methodology in metastatic renal cell carcinoma

Cancer care is currently experiencing rapid development in novel therapeutics, with an associated rise in treatment costs. These changes not only create a critical challenge for therapeutic decision-making but also highlight the need to prioritize therapies of high clinical and economic value. Healt...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Urology 2020-01, Vol.17 (1), p.3-5
Hauptverfasser:	Parmar, Ambica, Chan, Kelvin K. W.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/698/1864/272 692/700/1538 692/700/155 Antimitotic agents Antineoplastic agents Cancer Carcinoma, Renal Cell - secondary Carcinoma, Renal Cell - therapy Comment Decision making Health technology assessment Homeopathy Humans Kidney cancer Kidney Neoplasms - pathology Kidney Neoplasms - therapy Materia medica and therapeutics Medicine Medicine & Public Health Metastasis Methods Technology application Technology Assessment, Biomedical - methods Therapeutics Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Cancer care is currently experiencing rapid development in novel therapeutics, with an associated rise in treatment costs. These changes not only create a critical challenge for therapeutic decision-making but also highlight the need to prioritize therapies of high clinical and economic value. Health technology assessment methodology is a novel approach that could help guide value-based decision-making.
ISSN:	1759-4812 1759-4820
DOI:	10.1038/s41585-019-0257-4